Jupiter Endovascular Announces First Patients Successfully Treated in First Clinical Study of Vertex Pulmonary Embolectomy System Using Endoportal Control
Vertex System Designed to Bring the Precision and Control of Direct Surgical Access to Catheter-Based Interventions
Excerpt from the Press Release:
MENLO PARK, Calif.–(BUSINESS WIRE)–Jupiter Endovascular, Inc., a medical technology startup developing a new class of endovascular procedures using Endoportal Control™, announced today that the first two patients have been treated in SPIRARE I (NCT06571760), a multicenter study of the Vertex Pulmonary Embolectomy System using the company’s Endoportal Control™ platform technology. The Vertex system is designed to treat Acute Pulmonary Embolism (PE) in an innovative endovascular procedure offering an unprecedented level of control and precision.
The successful first two cases were performed at St. John Paul II Hospital in Krakow, Poland, a cardiothoracic specialist center affiliated with the Jagiellonian University, by study investigators Professor Grzegorz Kopec, MD, Jakub Stepniewski, MD, and Professor Krzysztof Bartus, MD.
“In these first cases, the Vertex system was successful in safely navigating through the right heart and into the pulmonary vasculature, facilitating an efficient and effective pulmonary embolectomy with no safety issues,” said Prof. Kopec, Head of the Team for the Diagnosis and Treatment of Pulmonary Circulatory Diseases at St. John Paul II Hospital. “The patients’ clinical condition and hemodynamics improved on the table during the procedure, and post-operative imaging showed noticeable improvements in right heart function.”
“Controlling interventional devices within the pulmonary arterial tree when treating patients with intermediate-risk and high-risk PE can be challenging with today’s commercially available technology,” said Dr. Stepniewski, the Pulmonary Embolism Response Team (PERT) Coordinator at St. John Paul II Hospital. “The endoportal technology enabled the large-bore Vertex system to remain stable in tachypneic patients, allowing us to quickly access and revascularize multiple areas of the pulmonary vasculature in a controlled manner when facing a high degree of cardiorespiratory movement.”
Click the button below to read the entire Press Release:
Discover What Sets TrialStat Apart From Ordinary EDC Platforms
Click the image or button below to explore our eClinical Suite Platform and discover what sets TrialStat apart from competing EDC platforms.
Request Your Demo Today!
From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?